Casey M Hay1, Madeleine Courtney-Brooks2, Carolyn Lefkowits3, Teresa L Hagan4, Robert P Edwards2, Heidi S Donovan5. 1. Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital of the University of Pittsburgh Medical Center, 300 Halket Street, Pittsburgh, PA 15213, USA. Electronic address: haycm2@upmc.edu. 2. Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital of the University of Pittsburgh Medical Center, 300 Halket Street, Pittsburgh, PA 15213, USA. 3. Division of Gynecologic Oncology, University of Colorado Denver, 1665 Aurora Court, Aurora, CO 80045, USA. 4. School of Nursing, University of Pittsburgh, 415 Victoria Building, 3500 Victoria Street, Pittsburgh, PA 15261, USA; Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA. 5. School of Nursing, University of Pittsburgh, 415 Victoria Building, 3500 Victoria Street, Pittsburgh, PA 15261, USA.
Abstract
OBJECTIVE: We sought to compare symptoms identified as a priority by patients with recurrent ovarian cancer to symptoms most frequently documented by their clinicians, and examine the association between clinician documentation of symptoms and subsequent clinical intervention. METHODS: Single-institution, retrospective chart review of patients enrolled in WRITE Symptoms Study (GOG 259), a randomized controlled trial of internet-based recurrent ovarian cancer symptom management. As part of the trial, women completed the Symptom Representation Questionnaire for 28 symptoms and selected 3 priority symptoms (PS). We compared patient-reported PS to clinician documentation of symptoms and interventions over the time period corresponding to study enrollment. RESULTS: At least one PS was documented in 92% of patients. Of 150 PS reported by patients, 53% were never documented by clinicians; these symptoms tended to be less directly related to disease or treatment status. Symptoms not identified by patients as PS were frequently documented by clinicians; these symptoms tended to relate to physiologic effects of disease and treatment toxicity. 58% of patients had at least one PS intervention. PS intervened for were documented at 2.58 visits vs 0.50 visits for PS not receiving intervention (p≤0.0001). CONCLUSIONS: Discordance was identified between symptoms reported by patients as important and symptoms documented by clinicians. Symptoms more frequently documented were also more frequently intervened for. Our study illustrates the need to improve identification of symptoms important to patients, and suggests that improving communication between patients and clinicians could increase intervention rates to enhance quality of life in women with recurrent ovarian cancer.
RCT Entities:
OBJECTIVE: We sought to compare symptoms identified as a priority by patients with recurrent ovarian cancer to symptoms most frequently documented by their clinicians, and examine the association between clinician documentation of symptoms and subsequent clinical intervention. METHODS: Single-institution, retrospective chart review of patients enrolled in WRITE Symptoms Study (GOG 259), a randomized controlled trial of internet-based recurrent ovarian cancer symptom management. As part of the trial, women completed the Symptom Representation Questionnaire for 28 symptoms and selected 3 priority symptoms (PS). We compared patient-reported PS to clinician documentation of symptoms and interventions over the time period corresponding to study enrollment. RESULTS: At least one PS was documented in 92% of patients. Of 150 PS reported by patients, 53% were never documented by clinicians; these symptoms tended to be less directly related to disease or treatment status. Symptoms not identified by patients as PS were frequently documented by clinicians; these symptoms tended to relate to physiologic effects of disease and treatment toxicity. 58% of patients had at least one PS intervention. PS intervened for were documented at 2.58 visits vs 0.50 visits for PS not receiving intervention (p≤0.0001). CONCLUSIONS: Discordance was identified between symptoms reported by patients as important and symptoms documented by clinicians. Symptoms more frequently documented were also more frequently intervened for. Our study illustrates the need to improve identification of symptoms important to patients, and suggests that improving communication between patients and clinicians could increase intervention rates to enhance quality of life in women with recurrent ovarian cancer.
Authors: Lisa M Landrum; Stephanie Blank; Lee-may Chen; Linda Duska; Victoria Bae-Jump; Paula S Lee; Lyuba Levine; Carolyn McCourt; Kathleen N Moore; Renata R Urban Journal: Gynecol Oncol Date: 2015-03-04 Impact factor: 5.482
Authors: Heidi S Donovan; Sandra E Ward; Susan M Sereika; Judith E Knapp; Paula R Sherwood; Catherine M Bender; Robert P Edwards; Margaret Fields; Renee Ingel Journal: J Pain Symptom Manage Date: 2013-09-07 Impact factor: 3.612
Authors: M Brundage; M Gropp; F Mefti; K Mann; B Lund; V Gebski; G Wolfram; N Reed; S Pignata; A Ferrero; C Brown; E Eisenhauer; E Pujade-Lauraine Journal: Ann Oncol Date: 2012-01-30 Impact factor: 32.976
Authors: Chantal Quinten; John Maringwa; Carolyn C Gotay; Francesca Martinelli; Corneel Coens; Bryce B Reeve; Henning Flechtner; Eva Greimel; Madeleine King; David Osoba; Charles Cleeland; Jolie Ringash; Joseph Schmucker-Von Koch; Martin J B Taphoorn; Joachim Weis; Andrew Bottomley Journal: J Natl Cancer Inst Date: 2011-12-07 Impact factor: 13.506
Authors: Teresa Thomas; Andrew Althouse; Lauren Sigler; Robert Arnold; Edward Chu; Douglas B White; Margaret Rosenzweig; Kenneth Smith; Thomas J Smith; Yael Schenker Journal: Psychooncology Date: 2021-03-08 Impact factor: 3.955
Authors: Mille Guldager Christiansen; Helle Pappot; Charlotte Pedersen; Mary Jarden; Mansoor Raza Mirza; Karin Piil Journal: Support Care Cancer Date: 2021-11-18 Impact factor: 3.603
Authors: Chloe A Logue; Julia Pugh; Philip Foden; Reem D Mahmood; Robert D Morgan; Claire Mitchell; Jurjees Hasan; Andrew R Clamp; Gordon C Jayson Journal: Sex Med Date: 2021-12-15 Impact factor: 2.491
Authors: Yeh Chen Lee; Madeleine T King; Rachel L O'Connell; Anne Lanceley; Florence Joly; Felix Hilpert; Alison Davis; Felicia T Roncolato; Aikou Okamoto; Jane Bryce; Paul Donnellan; Amit M Oza; Elisabeth Avall-Lundqvist; Jonathan S Berek; Jonathan A Ledermann; Dominique Berton; Jalid Sehouli; Amanda Feeney; Marie-Christine Kaminsky; Katrina Diamante; Martin R Stockler; Michael L Friedlander Journal: Int J Gynecol Cancer Date: 2022-06-06 Impact factor: 4.661